Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | FECH | P22830 | 1/20 | 0.38 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.38 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | TPO | P07202 | 1/20 | 0.34 |
| ▸ | EPX | P11678 | 1/20 | 0.34 |
| ▸ | LPO | P22079 | 1/20 | 0.34 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.34 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29887886 | 1.00 | EGFR (0.38) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL29414877 | 0.84 | ERBB2 (0.48) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL20172422 | 0.84 | ERBB2 (0.40) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL1192195 | 0.84 | ERBB2 (0.48) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL30314880 | 0.84 | ERBB2 (0.38) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24167904 | 0.84 | ERBB2 (0.38) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL23747132 | 0.84 | BACE1 (0.34) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24167718 | 0.82 | MPO (0.35) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24167309 | 0.82 | EGFR (0.57) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24995754 | 0.82 | DYRK1A (0.42) | EGFRERBB2PDE7AHTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426697-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118103370-A | Fused tetracyclic quinazoline derivatives as ERBB2 inhibitors | 英莱汶公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117980309-A | Tricyclic fused pyrimidine compounds useful as HER2 inhibitors | 百时美施贵宝公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240124474-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240116921-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2024-04-11 | — | — | US | disclosed |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230382923-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382923-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022003575-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021231400-A1 | BIS-ARYL ETHERS CONTAINING N-ACYL AZETIDINE AS EGFR/HER2 INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021156180-A1 | [1,3]DIAZINO[5,4-D]PYRIMIDINES AS HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-08-12 | — | — | WO | disclosed |
| EP-3677583-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2020-07-08 | — | — | EP | disclosed |
| US-20200190091-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190091-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885NQO2 1434/4885 |
| US-20240116921-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, FGFR2, ERBB3 | EGFR 5/4885ERBB2 1/4885NQO2 1206/4885 |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885NQO2 405/4885 |
| US-20240124474-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885NQO2 772/4885 |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | EGFR 13/4885ERBB2 1/4885NQO2 1493/4885 |
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ERBB2, ERBB3, BRCA1 | EGFR 5/4885ERBB2 1/4885NQO2 1814/4885 |
| US-20230382923-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, BRCA1 | EGFR 5/4885ERBB2 1/4885NQO2 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.